Cannabinoid receptor type 1 antagonist inhibits progression of obesity‐associated nonalcoholic steatohepatitis in a mouse model by remodulating immune system disturbances

Autor: Chin‐Chang Chen, Zi‐Yu Chang, Fuu‐Jen Tsai, Shih‐Yin Chen

Publikováno v: Immunity, Inflammation and Disease, Vol 8, Iss 4, Pp 544-558 (2020)

Abstract Scope This study investigated whether AM251, a cannabinoid receptor type 1 (CB1) antagonist, ameliorates hepatic levels of metabolic abnormalities and inflammatory responses in a murine nonalcoholic steatohepatitis (NASH) model via reversal

Externí odkaz: https://doaj.org/article/828adeb65eba4ef28c2e6950f0a487ae

WIN55,212-2, a Dual Modulator of Cannabinoid Receptors and G Protein-Coupled Inward Rectifier Potassium Channels

Autor: Dongchen An, Steve Peigneur, Jan Tytgat

Publikováno v: Biomedicines, Vol 9, Iss 5, p 484 (2021)

The coupling of cannabinoid receptors, CB1 and CB2, to G protein-coupled inward rectifier potassium channels, GIRK1 and GIRK2, modulates neuronal excitability in the human brain. The present study established and validated the functional expression i

Externí odkaz: https://doaj.org/article/6214aa0f249a4ddb94f6915ffadc1b34

Targeting Cannabinoid Receptors: Current Status and Prospects of Natural Products

Autor: Louise Antonia Hendrickx, Jan Tytgat, Dongchen An, Steve Peigneur

Publikováno v: International Journal of Molecular Sciences
International Journal of Molecular Sciences, Vol 21, Iss 5064, p 5064 (2020)

Cannabinoid receptors (CB1 and CB2), as part of the endocannabinoid system, play a critical role in numerous human physiological and pathological conditions. Thus, considerable efforts have been made to develop ligands for CB1 and CB2, resulting in h

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3896a859f89530b064bd08f693acb9b
https://pubmed.ncbi.nlm.nih.gov/32709050

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Rimonabant, a potent CB1 cannabinoid receptor antagonist, is a Gα; i/o; protein inhibitor

Autor: Alessandra Porcu, Miriam Melis, Bernhard Bettler, Rostislav Turecek, Ignazia Mocci, Gian Luigi Gessa, Celine Ullrich, M. Paola Castelli

Publikováno v: Neuropharmacology 133 (2018): 107–120. doi:10.1016/j.neuropharm.2018.01.024
info:cnr-pdr/source/autori:Porcu A, Melis M, Turecek R, Ullrich C, Mocci I, Bettler B, Gessa GL, Castelli MP./titolo:Rimonabant, a potent CB1 cannabinoid receptor antagonist, is a G?(i%2Fo) protein inhibitor/doi:10.1016%2Fj.neuropharm.2018.01.024/rivista:Neuropharmacology/anno:2018/pagina_da:107/pagina_a:120/intervallo_pagine:107–120/volume:133

Rimonabant is a potent and selective cannabinoid CB1 receptor antagonist widely used in animal and clinical studies. Besides its antagonistic properties, numerous studies have shown that, at micromolar concentrations rimonabant behaves as an inverse

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd14ef8453f3c0ffb9727e91fdb52a9a